BioSpace News Archive

The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.

Synthekine Inc., a leader in engineered cytokine therapeutics, today announced that the company has completed phase 1a dose escalation and dosed the first patient in the Phase 1b portion of a clinical trial evaluating its α/β biased IL-2, STK-012, for the treatment of solid tumors.

Anbio Biotechnology, a leading global diagnostic device and assay company, has announced its participation in the AACC Middle East 2023 in Dubai on October 7-8, 2023.

Specialty cancer diagnostics company Precipio, Inc. announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new analysis of clinical trial data for INPEFA® (sotagliflozin) will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, October 6-9, 2023 in Cleveland, Ohio.

Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, announced that senior management will participate in the following investor conferences in October.

Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data-driven precision medicine to obesity treatment, announced today the United States Patent and Trademark Office (USPTO) has issued the first patent related to its obesity phenotyping technology.

Centinel Spine®, LLC, (“the Company”) a leading global medical device company addressing cervical and lumbar spinal disease by providing the most robust and clinically-proven total disc replacement (TDR) technology platform in the world (prodisc®), today announced the completion of the 2,500th case in the U.S. with the prodisc C Vivo and prodisc C SK Cervical TDR System.

Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, and GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the expansion of their pilot to offer GRAIL’s groundbreaking Galleri® multi-cancer early detection screening test.

Immunis, Inc., a private biotech company creating novel cellular secretome therapies for age and disease-related immune decline, is delighted to have Professor Irina Conboy on its Scientific Advisory Board.